Key facts for NCD 190.12
- Benefit category
- Diagnostic Laboratory Tests
- Effective date
- 11/25/2002
- Implemented 01/01/2003
- Transmittal
- Transmittal 17
- Versions published
- 1
- Lab edit list
- 764 covered ICD-10
- 233 non-covered
TL;DR
NCD 190.12 sets Medicare's national policy for urine culture, bacterial under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. • A patient's urinalysis is abnormal suggesting urinary tract infection, for example, abnormal microscopic (hematuria, pyuria, bacteriuria); abnormal biochemical urinalysis (positive leukocyte esterase, nitrite, protein, blood); a Gram's stain positive… As a laboratory NCD it carries a national ICD-10 edit list: 764 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 2 procedure codes.
Item or service described
A bacterial urine culture is a laboratory procedure performed on a urine specimen to establish the probable etiology of a presumed urinary tract infection. It is common practice to do a urinalysis prior to a urine culture. A urine culture may also be used as part of the evaluation and management of another related condition. The procedure includes aerobic agar-based isolation of bacteria or other cultivable organisms present, and quantification of types present based on morphologic criteria. Isolates deemed significant may be subjected to additional identification and susceptibility procedures as requested by the ordering physician. The physician's request may be through clearly documented and communicated laboratory protocols.
Indications and limitations of coverage
Indications
• A patient's urinalysis is abnormal suggesting urinary tract infection, for example, abnormal microscopic (hematuria, pyuria, bacteriuria); abnormal biochemical urinalysis (positive leukocyte esterase, nitrite, protein, blood); a Gram's stain positive for microorganisms; positive bacteriuria screen by a non-culture technique; or other significant abnormality of a urinalysis. While it is not essential to evaluate a urine specimen by one of these methods before a urine culture is performed, certain clinical presentations with highly suggestive signs and symptoms may lend themselves to an antecedent urinalysis procedure where follow-up culture depends upon an initial positive or abnormal test result.
• A patient has clinical signs and symptoms indicative of a possible urinary tract infection (UTI). Acute lower UTI may present with urgency, frequency, nocturia, dysuria, discharge or incontinence. These findings may also be noted in upper UTI with additional systemic symptoms (for example, fever, chills, lethargy); or pain in the costovertebral, abdominal, or pelvic areas. Signs and symptoms may overlap considerably with other inflammatory conditions of the genitourinary tract (for example, prostatitis, urethritis, vaginitis, or cervicitis). Elderly or immunocompromised patients, or patients with neurologic disorders may present atypically (for example, general debility, acute mental status changes, declining functional status).
• The patient is being evaluated for suspected urosepsis, fever of unknown origin, or other systemic manifestations of infection but without a known source. Signs and symptoms used to define sepsis have been well established.
• A test-of cure is generally not indicated in an uncomplicated infection. However, it may be indicated if the patient is being evaluated for response to therapy and there is a complicating co-existing urinary abnormality including structural or functional abnormalities, calculi, foreign bodies, or ureteral/renal stents or there is clinical or laboratory evidence of failure to respond as described in Indications 1 and 2.
• In surgical procedures involving major manipulations of the genitourinary tract, preoperative examination to detect occult infection may be indicated in selected cases (for example, prior to renal transplantation, manipulation or removal of kidney stones, or transurethral surgery of the bladder or prostate).
• Urine culture may be indicated to detect occult infection in renal transplant recipients on immunosuppressive therapy.
Limitations
• CPT 87086 may be used one time per encounter.
• Colony count restrictions on coverage of CPT 87088 do not apply as they may be highly variable according to syndrome or other clinical circumstances (for example, antecedent therapy, collection time, degree of hydration).
• CPT 87088, 87184, and 87186 may be used multiple times in association with or independent of 87086, as urinary tract infections may be polymicrobial.
• Testing for asymptomatic bacteriuria as part of a prenatal evaluation may be medically appropriate but is considered screening and, therefore, not covered by Medicare. The US Preventive Services Task Force has concluded that screening for asymptomatic bacteriuria outside of the narrow indication for pregnant women is generally not indicated. There are insufficient data to recommend screening in ambulatory elderly patients including those with diabetes. Testing may be clinically indicated on other grounds including likelihood of recurrence or potential adverse effects of antibiotics, but is considered screening in the absence of clinical or laboratory evidence of infection.
Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).
Text reproduced from the CMS Medicare Coverage Database record for NCD 190.12 version 1. View the original on cms.gov.
Laboratory NCD code lists (October 2026)
Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 764 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.
2 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.
| Code | Code set |
|---|---|
| 87086 | CPT (descriptor licensed by AMA) |
| 87088 | CPT (descriptor licensed by AMA) |
What Medicare pays for these tests: 2 of the 2 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $8.07 to $8.09, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.
| Code | CLFS amount | With QW | Pricing |
|---|---|---|---|
| 87086 | $8.07 | — | national payment amount |
| 87088 | $8.09 | — | national payment amount |
The first 40 of 764 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.
| ICD-10-CM | Description | Effective |
|---|---|---|
| A02.1 | Salmonella sepsis | 2015-10-01 |
| A18.14 | Tuberculosis of prostate | 2015-10-01 |
| A34 | Obstetrical tetanus | 2015-10-01 |
| A40.0 | Sepsis due to streptococcus, group A | 2015-10-01 |
| A40.1 | Sepsis due to streptococcus, group B | 2015-10-01 |
| A40.3 | Sepsis due to Streptococcus pneumoniae | 2015-10-01 |
| A40.8 | Other streptococcal sepsis | 2015-10-01 |
| A40.9 | Streptococcal sepsis, unspecified | 2015-10-01 |
| A41.01 | Sepsis due to Methicillin susceptible Staphylococcus aureus | 2015-10-01 |
| A41.02 | Sepsis due to Methicillin resistant Staphylococcus aureus | 2015-10-01 |
| A41.1 | Sepsis due to other specified staphylococcus | 2015-10-01 |
| A41.2 | Sepsis due to unspecified staphylococcus | 2015-10-01 |
| A41.3 | Sepsis due to Hemophilus influenzae | 2015-10-01 |
| A41.4 | Sepsis due to anaerobes | 2015-10-01 |
| A41.50 | Gram-negative sepsis, unspecified | 2015-10-01 |
| A41.51 | Sepsis due to Escherichia coli [E. coli] | 2015-10-01 |
| A41.52 | Sepsis due to Pseudomonas | 2015-10-01 |
| A41.53 | Sepsis due to Serratia | 2015-10-01 |
| A41.54 | Sepsis due to Acinetobacter baumannii | 2023-10-01 |
| A41.59 | Other Gram-negative sepsis | 2015-10-01 |
| A41.81 | Sepsis due to Enterococcus | 2015-10-01 |
| A41.89 | Other specified sepsis | 2015-10-01 |
| A41.9 | Sepsis, unspecified organism | 2015-10-01 |
| A42.7 | Actinomycotic sepsis | 2015-10-01 |
| A56.01 | Chlamydial cystitis and urethritis | 2015-10-01 |
| A56.02 | Chlamydial vulvovaginitis | 2015-10-01 |
| A56.11 | Chlamydial female pelvic inflammatory disease | 2015-10-01 |
| D65 | Disseminated intravascular coagulation [defibrination syndrome] | 2015-10-01 |
| D70.0 | Congenital agranulocytosis | 2015-10-01 |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy | 2015-10-01 |
| D70.2 | Other drug-induced agranulocytosis | 2015-10-01 |
| D70.3 | Neutropenia due to infection | 2015-10-01 |
| D70.4 | Cyclic neutropenia | 2015-10-01 |
| D70.8 | Other neutropenia | 2015-10-01 |
| D70.9 | Neutropenia, unspecified | 2015-10-01 |
| D72.89 | Other specified disorders of white blood cells | 2015-10-01 |
| E09.21 | Drug or chemical induced diabetes mellitus with diabetic nephropathy | 2015-10-01 |
| E09.22 | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease | 2015-10-01 |
| E09.29 | Drug or chemical induced diabetes mellitus with other diabetic kidney complication | 2015-10-01 |
| E11.10 | Type 2 diabetes mellitus with ketoacidosis without coma | 2017-10-01 |
233 diagnosis codes deny automatically under this NCD; the first 20 are shown.
| ICD-10-CM | Description |
|---|---|
| R99 | Ill-defined and unknown cause of mortality |
| Z00.00 | Encounter for general adult medical examination without abnormal findings |
| Z00.01 | Encounter for general adult medical examination with abnormal findings |
| Z00.110 | Health examination for newborn under 8 days old |
| Z00.111 | Health examination for newborn 8 to 28 days old |
| Z00.121 | Encounter for routine child health examination with abnormal findings |
| Z00.129 | Encounter for routine child health examination without abnormal findings |
| Z00.5 | Encounter for examination of potential donor of organ and tissue |
| Z00.6 | Encounter for examination for normal comparison and control in clinical research program |
| Z00.70 | Encounter for examination for period of delayed growth in childhood without abnormal findings |
| Z00.71 | Encounter for examination for period of delayed growth in childhood with abnormal findings |
| Z00.8 | Encounter for other general examination |
| Z02.0 | Encounter for examination for admission to educational institution |
| Z02.1 | Encounter for pre-employment examination |
| Z02.2 | Encounter for examination for admission to residential institution |
| Z02.3 | Encounter for examination for recruitment to armed forces |
| Z02.4 | Encounter for examination for driving license |
| Z02.5 | Encounter for examination for participation in sport |
| Z02.6 | Encounter for examination for insurance purposes |
| Z02.71 | Encounter for disability determination |
Changed in October 2026
The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 11 codes.
Codes on this NCD's list by release: October 2025: 986 · January 2026: 997 · October 2026: 997. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.
Revision history
07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)
07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)
How this NCD shows up on remittances
A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.
For teams evaluating QuickIntell software
Evaluate a coverage-review workflow around NCD 190.12
Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — NCD 190.12
What does NCD 190.12 cover?
• A patient's urinalysis is abnormal suggesting urinary tract infection, for example, abnormal microscopic (hematuria, pyuria, bacteriuria); abnormal biochemical urinalysis (positive leukocyte esterase, nitrite, protein, blood); a Gram's stain positive for microorganisms; positive bacteriuria screen by a non-culture technique; or other significant abnormality of a urinalysis. While it is not essential to evaluate… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.
When did NCD 190.12 take effect?
The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.
Does a Local Coverage Determination override NCD 190.12?
No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).
Which diagnosis codes are covered under NCD 190.12?
The October 2026 laboratory NCD edit list contains 764 ICD-10-CM codes that support urine culture, bacterial (for example A02.1 Salmonella sepsis; A18.14 Tuberculosis of prostate; A34 Obstetrical tetanus) and 233 codes that deny. The list applies to 87086, 87088.
How often does the lab NCD code list for 190.12 change?
CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.
CMS guidance
Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:
- Complying With Documentation Requirements for Lab Services(MLN909221, )What documentation supports a laboratory claim: the order, the medical necessity and the results.
- Clinical Laboratory Fee Schedule(MLN006818, )How the Clinical Laboratory Fee Schedule is set, including data reporting and the payment determination.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database NCDs via the CMS Coverage APIVersion API snapshot 2026-09-27 · effective 2026-09-20 · file national-coverage-ncd.jsonSHA-256 a90fadfd264b9ef4…
- Laboratory NCD ICD-10 code lists, October 2026Version October 2026 · effective 2026-10-01 · file 2026400-Initial-ICD10-NCD-Spreadsheet-20260601-508.xlsxSHA-256 ec4361dc65f63432…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.